Literature DB >> 8774355

A sigma ligand, SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice.

B Bourrié1, J M Benoît, J M Derocq, M Esclangon, C Thomas, G Le Fur, P Casellas.   

Abstract

Sigma receptors originally described in distinct regions of the central nervous system are expressed on cells of the immune system. A sigma ligand, SR 31747A, was observed here to inhibit in vitro the Staphylococcal enterotoxin B (SEB)-driven lymphocyte proliferation. In mice, the drug confers a potent protection against the lethality induced by SEB, stimulates the SEB-induced serum release of interleukin (IL)-10 and inhibits at the same time the systemic release of IL-2, IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6 and tumour necrosis factor-alpha (TNF-alpha). The enhancement of IL-10 production by this compound is also effective in nude mice treated with SEB, indicating that IL-10 of T-cell origin is not involved in this process. The finding that a sigma ligand protects against the SEB-induced toxicity provides insights into the clinical use of this family of compounds, particularly in food poisoning and septic shock where Staphylococcal enterotoxins are involved. The observation that this compound stimulates IL-10 synthesis indicates that it could be a potent regulatory agent of chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774355      PMCID: PMC1456335          DOI: 10.1046/j.1365-2567.1996.d01-657.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  Allosteric modulation of peripheral sigma binding sites by a new selective ligand: SR 31747.

Authors:  R Paul; S Lavastre; D Floutard; R Floutard; X Canat; P Casellas; G Le Fur; J C Brelière
Journal:  J Neuroimmunol       Date:  1994-07       Impact factor: 3.478

2.  Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10.

Authors:  A O'Garra; G Stapleton; V Dhar; M Pearce; J Schumacher; H Rugo; D Barbis; A Stall; J Cupp; K Moore
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

3.  Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses.

Authors:  P Casellas; B Bourrié; X Canat; P Carayon; I Buisson; R Paul; J C Brelière; G Le Fur
Journal:  J Neuroimmunol       Date:  1994-07       Impact factor: 3.478

4.  Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock.

Authors:  A G Bean; R A Freiberg; S Andrade; S Menon; A Zlotnik
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

5.  IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells.

Authors:  H Yssel; R De Waal Malefyt; M G Roncarolo; J S Abrams; R Lahesmaa; H Spits; J E de Vries
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

6.  Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis.

Authors:  C Q Chu; M Field; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  1991-09

7.  Functional assessment and partial characterization of [3H](+)-pentazocine binding sites on cells of the immune system.

Authors:  D J Carr; B R De Costa; L Radesca; J E Blalock
Journal:  J Neuroimmunol       Date:  1991-12       Impact factor: 3.478

8.  Linomide, a novel immunomodulator that prevents death in four models of septic shock.

Authors:  J A Gonzalo; A González-García; T Kalland; G Hedlund; C Martínez; G Kroemer
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

9.  T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.

Authors:  T Miethke; C Wahl; K Heeg; B Echtenacher; P H Krammer; H Wagner
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

10.  Immunoregulatory role of interleukin 10 in rheumatoid arthritis.

Authors:  P D Katsikis; C Q Chu; F M Brennan; R N Maini; M Feldmann
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

View more
  6 in total

1.  A DNA microarray-based approach to elucidate the effects of the immunosuppressant SR31747A on gene expression in Saccharomyces cerevisiae.

Authors:  Elisa Cinato; Annick Péléraux; Sandra Silve; Sylvaine Galiègue; Christiane Dhers; Claudine Picard; Omar Jbilo; Gérard Loison; Pierre Casellas
Journal:  Gene Expr       Date:  2002

2.  SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2013-04-28       Impact factor: 5.330

Review 3.  Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes.

Authors:  Halley M Oyer; Christina M Sanders; Felix J Kim
Journal:  Front Pharmacol       Date:  2019-10-21       Impact factor: 5.810

4.  Inhibitory effects of sigma-2 receptor agonists on T lymphocyte activation.

Authors:  Miguel A Iñiguez; Carmen Punzón; Raquel Nieto; Javier Burgueño; José M Vela; Manuel Fresno
Journal:  Front Pharmacol       Date:  2013-03-13       Impact factor: 5.810

5.  SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo.

Authors:  Y Berthois; B Bourrié; S Galiègue; H Vidal; P Carayon; P M Martin; P Casellas
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

Review 6.  Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases.

Authors:  Jia Jia; Jian Cheng; Cheng Wang; Xuechu Zhen
Journal:  Front Cell Neurosci       Date:  2018-09-20       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.